menu
    • menu
    [{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Denver \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"Joslin Diabetes Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Joslin Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joslin Diabetes Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Joslin Diabetes Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cheryl Rosenfeld","sponsor":"Amylin Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Cheryl Rosenfeld","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cheryl Rosenfeld \/ Amylin Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Cheryl Rosenfeld \/ Amylin Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1 | Amylin receptor AMY3; CALCR\/RAMP3 | Amylin receptor AMY2; CALCR\/RAMP2","graph1":"Endocrinology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Pramlintide","moa":"Amylin receptor AMY1, CALCR\/RAMP1 | Amylin receptor AMY3; CALCR\/RAMP3 | Amylin receptor AMY2; CALCR\/RAMP2","graph1":"Endocrinology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"Adocia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adocia \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Pramlintide

    Menu

    Pramlintide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adocia

                            France arrow
                            AAPS
                            Not Confirmed

                            Adocia

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro,Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

                            Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

                            Product Name : BC LisPram

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 29, 2021

                            Lead Product(s) : Insulin Lispro,Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adocia

                            France arrow
                            AAPS
                            Not Confirmed

                            Adocia

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide,Exenatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinat...

                            Details : Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide-both combinations demonstrated promising effects in obesity treatment.

                            Product Name : PramExe

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 26, 2021

                            Lead Product(s) : Pramlintide,Exenatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Xeris Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide,Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of XP-3924 in Adul...

                            Details : XP-3924 resulted in 62% reduction of hyperglycemia after a glucose challenge. XP-3924 showed promising glucose control when compared to both Humulin R and co-administered injections of Humulin R & Symlin and it showed improved glucose control when compar...

                            Product Name : Xerisol

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2020

                            Lead Product(s) : Pramlintide,Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

                            Details : Pramlintide Acetate is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 17, 2015

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Joslin Diabetes Center

                            Country arrow
                            AAPS
                            Not Confirmed

                            Joslin Diabetes Center

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

                            Details : Pramlintide is a Other Large Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypoglycemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 26, 2013

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

                            Details : Pramlintide Acetate is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 16, 2012

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Juvenile Diabetes Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

                            Details : Pramlintide is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 07, 2010

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of Colorado, Denver

                            Country arrow
                            AAPS
                            Not Confirmed

                            University of Colorado, Denver

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Amylin Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

                            Details : Pramlintide is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2010

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Amylin Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cheryl Rosenfeld

                            Country arrow
                            AAPS
                            Not Confirmed

                            Cheryl Rosenfeld

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Amylin Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

                            Details : Pramlintide is a Other Large Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 04, 2010

                            Lead Product(s) : Pramlintide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Amylin Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth